Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × rrCLL × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 761 Lymphoma 710 Leukemia, Lymphocytic, Chronic, B-Cell 556 Lymphoma, Follicular 508 Lymphoma, Large B-Cell, Diffuse 439 Precursor Cell Lymphoblastic Leukemia-Lymphoma 328 Recurrence 315 Lymphoma, B-Cell 292 Neoplasms 260 Lymphoma, Mantle-Cell 248 Leukemia 228 Multiple Myeloma 188 Hodgkin Disease 178 Leukemia, Myeloid, Acute 176 Lymphoma, B-Cell, Marginal Zone 134 Lymphoma, T-Cell, Peripheral 118 Burkitt Lymphoma 104 Hematologic Neoplasms 100 Myelodysplastic Syndromes 99 Lymphoma, T-Cell, Cutaneous 88 Waldenstrom Macroglobulinemia 82 Leukemia, B-Cell 79 Lymphoma, T-Cell 74 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 65 Lymphoproliferative Disorders 57 Hematologic Diseases 57 Melanoma 54 Carcinoma, Non-Small-Cell Lung 53 Breast Neoplasms 51 Mycosis Fungoides 49

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡